Findings of what is believed to be the first non-randomized study of immune checkpoint blockade in parents with high-risk oral precancer, was published in JAMA Oncology.
A next step would be to consider a larger, precision immunotherapy randomized study favouring cancer-free survival (CFS) as a primary outcome and stratified by prior history of early-stage treated OSCC and 9p21.3 loss according to Dr. Glenn J. Hanna of the Department of Medical Oncology, Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School in Boston, MA, US, and colleagues who published their findings on 16 November 2023 in the JAMA Oncology. The precancer in question, oral leukoplakia, "refers to a white plaque of variable cancer risk, having excluded other conditions, and affects up to 5% of the global population." The authors of the study further caution that overtreatment of premalignant conditions is a concern, recommending that "evidence-based standards for adoption should be more stringent."
To read more about this study, click here.
Sources mentioned:
- Hanna GJ, Villa A, Nandi SP, et al. Nivolumab for Patients With High-Risk Oral Leukoplakia A Nonrandomized Controlled Trial. JAMA Oncol; Published online 16 November 2023. doi:10.1001/jamaoncol.2023.4853
- Gyawali B, Strohbehn GW. Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation? JAMA Oncol. Published online November 16, 2023. doi:10.1001/jamaoncol.2023.4799
No comments:
Post a Comment